XML 68 R63.htm IDEA: XBRL DOCUMENT v3.19.3
EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Jun. 13, 2019
Sep. 28, 2019
Sep. 29, 2018
Sep. 28, 2019
Sep. 29, 2018
Aug. 28, 2019
Apr. 29, 2019
Vital River              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Additional equity interest percentage purchased (5.00%)            
Ownership percentage 92.00%            
Noncontrolling interest ownership percentage 8.00%            
Citoxlab              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Ownership percentage             90.00%
Noncontrolling interest ownership percentage             10.00%
Supplier              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Ownership percentage           80.00%  
Noncontrolling interest ownership percentage           20.00% 20.00%
Employee Stock Option              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Antidilutive securities excluded from computation of earnings per share amount (in shares)   0.4 0.5 0.4 0.5    
Restricted Stock and Restricted Stock Units              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Antidilutive securities excluded from computation of earnings per share amount (in shares)       1.0 1.0    
Vital River              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Purchase of additional equity interest $ 7.9            
Gain in equity equal to the excess fair value of additional equity interest purchase 0.8            
Contractually defined redemption value   $ 14.5   $ 14.5      
Vital River | Selling, general and administrative              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Charges equal to the excess fair value of hybrid equity instrument $ 2.2            
Citoxlab              
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]              
Contractually defined redemption value   $ 4.0   $ 4.0